Диссертация (1140048), страница 19
Текст из файла (страница 19)
Changes of natriureticpeptides predict hospital admissions in patients with chronic heart failure: a metaanalysis. JACC Heart Fail. 2014 Apr;2(2):148-58.159.Schmitt J, Duray G, Gersh BJ, Hohnloser SH. Atrial fibrillation in acutemyocardial infarction: a systematic review of the incidence, clinical features andprognostic implications. Eur Heart J 2009;30:1038–1045.160. Schotten U., Ausma J., Stellbrink C., et al. Cellular mechanisms ofdepressed atrial contractilityinpatientswithchronic atrialfibrillation.Circulation. 2001 Feb 6;103(5):691-8.161. Schotten U., Verheule S., Kirchhof P., et al.
Pathophysiological mechanismsof atrial fibrillation—a translational appraisal. Physiol Rev 2011 Jan;91(1):265325.162. Shantsila E, Shantsila A, Blann AD, Lip GY. Left ventricular fibrosis inatrial fibrillation. Am J Cardiol. 2013 Apr 1;111(7):996-1001.115163. Sinclair H., Paterson M., Walker S., et al. Predicting outcome in patientswith acute coronary syndrome: evaluation of B-type natriuretic peptide and theglobal registry of acute coronary events (GRACE) risk score. Scott Med J.
2007Aug;52(3):8-13.164. Song, M.H. Clinical Implication of Atrial and Brain Natriuretic Peptide inCoronary Artery Bypass Grafting/ M.H. Song, Y. Kobayashi, H. Michi. //AsianCardiovasc. Thorac. Ann. 2004. - Vol.l2.-№l.- P. 41-46.165. Stewart S, Hart C.L., Hole D.J., McMurray J.J. Population prevalence,incidence and predictirs of atrial fibrillation in the Renfrew/Paisley study. Heart2001; 86: 516-521.166. Stewart S, Murphy NF, Walker A, McGuire A, McMurrey JJ. Cost ofan emerging epidemic: an economic analysis of atrial fibrillation in theUK.//Heart 2004; 90: 286–92.167.
Sudoh Т., Kangawa K., Minamino N. et al. A new natriuretic peptide inporcine brain. Nature. 1988. - Vol. 332. - P. 78-81.168. Sullivan S.D., Orme M.E., Morais E., Mitchell S.A. Interventions for thetreatment of atrial fibrillation: a systematic literature review and meta-analysis. IntJ Cardiol.
2013 May 10;165(2):229-36.169. Sundstrom J., Evans J., Benjamin E. et al. Relations of plasma total TIMP41levels to cardiovascular risk factors and echocardiographic measures: theFramingham heart study // Eur. Heart J. – 2004. – [Vol.] 25. – P. 1509–1516.170. Susette Krohn Therkelsen, Bjoern Aaris Groenning, et al.
ANP and BNP inatrial fibrillation before and after cardioversion – and their relationship to cardiacvolume and function. International Journal of Cardiology 127 (2008) 396–399.171. Sussman M., Menzin J., Lin I., et al. Impact of atrial fibrillation on strokerelated healthcare costs. J Am Heart Assoc. 2013 Nov 25;2(6).172. Takagaki M, McCarthy PM, Chung M .Preload-adjusted maximal power: anovel index of left ventricular contractility in atrial fibrillation.// Heart., 2002, Aug,vol 88(2), р.170-176116173.Therkelsen SK, Groenning BA, Kjaer A, et al. ANP and BNP in atrialfibrillation before and after cardioversion--and their relationship to cardiac volumeand function.
Int J Cardiol. 2008 Jul 21;127(3):396-9.174. Thomas L, Boyd A, Thomas SP, Schiller NB, Ross DL. Atrial structuralremodelling and restoration of atrial contraction after linear ablation for atrialfibrillation.// Eur. Heart. J., 2003, Nov; vol 24(21), р.1942-1951.175. Thomas J.,Wang MD, Martin G., et al. Temporal relations of atrial fibrillationand congestive heart failure and their joint influence on mortality (Framinghamheart study). Circulation.
2003; 107: 2920-2925.176. Van Den Berg M.P., Crijns H.J.,et al. Atrial natriuretic peptide in patientswith heart failure and chronic atrial fibrillation: role of duration of atrialfibrillation. Am Heart J. 1998 Feb;135(2 Pt 1):242-4.177. Van den Berg M., Tjeerdsma G., et al. Longstanding atrial fibrillation causesdepletion of natriuretic peptide in patients with advanced congestive heart failure. /// Europ.
J. Heart. 2002. - № 4. - P. 255-262.178. Van Den Berg M.P., van Gelder I.C., van Veldhuisen D.J. Depletion ofatrial natriuretic peptide during longstanding atrial fibrillation. Europace. 2004Sep;6(5):433-7.179. Van der Zee P.M., Verberne HJ, et al. Relation of N-terminal pro B-typenatriuretic peptide levels after symptom-limited exercise to baseline and ischemialevels. Am J Cardiol. 2009 Mar 1;103(5):604-10.180. Van Gelder I.C., Hagens V.E., Bosker H.A., et al. A comparison of ratecontrol and rhythm control in patients with recurrent persistent atrial fibrillation. NEng J Med 2002; 347: 1834-1840.181. Van Gelder I.C., Van Veldhuisen D.J., Crijns H.J., et al. Rate ControlEfficacy in permanent atrial fibrillation: a comparison between lenient versus strictrate control in patients with and without heart failure: background, aims, anddesign of RACE II. Am Heart J 2006;152:420—426.182.
Verdecchia P, Reboldi G, Gattobigio R et all. Atrial fibrillation inhypertension: predictors and outcome.// Hypertension, 2003; 41; 218-223.117183. Waldo A.L., Wit A.L. Mechanisms of cardiac arrhythmias // The Lancet.1993. - Vol.341. - P.1189-1193.184. Wallen Т., Landahl S., Hedner T. et al. Brain natriuretic peptide in an elderlypopulation. J. Intern. Med. 1997. - Vol. 242. - P. 307-311.185. Wang, T.J. Temporal relation of atrial fibrillation and congestive heart failureand their joint influence on mortality: the Framigham Heart Study // Circulation. –2003. – Vol. 107. – P.
2920 -2925.186. Wazni O.M., Martin D.O., Marrouche N.F., et al. Plasma B-type natriureticpeptide levels predict postoperative atrial fibrillation in patients undergoing cardiacsurgery. Circulation. 2004 Jul 13;110(2):124-7.187. Wei G., Yaqi R., Ningfu W., et al. N-terminal prohormone B-type natriureticpeptide and cardiovascular risk in stable coronary artery disease: a meta-analysis ofnine prospective studies.
Rev Cardiovasc Med. 2013;14(2-4):e92-8.188. White M., McKelve R.S., Hall C. Natriuretic peptides predict left ventricularremodeling in response to metoprolol CR in patients with congestive heart failure:the RESOLVD phase II neurohumoral substudy. J. Card. Fail. 2001. - Vol. 7 (3). P. 28.189. Wijffels MC, Kirchhof CJ, Dorland R, et al. Atrial fibrillation begets atrialfibrillation. A study in awake chronically instrumented goats.//Circulation 1995,vol 92, p 1954-1968.190. Wozakowska-Kapłon B., Opolski G., Janion M., et al. Plasma concentrationof atrial natriuretic peptide is related to the duration of atrial fibrillation in patientswith advanced heart failure.
Kardiol Pol. 2004 Dec;61(12):513-21;191. Wozakowska-Kaplon B., Opolski G. Atrial natriuretic peptide levelafter cardioversion ofchronicatrialfibrillation.IntJCardiol. 2002May;83(2):159-65.192. Wozakowska-Kaplon B. Changes in plasma natriuretic peptide levels inpatients with atrial fibrillation after cardioversion.Int J Cardiol. 2010 Oct29;144(3):436-7.118193. Yamamoto K., Tsusumoto Т., Wada A.et al., BNP and heart failure: clinicalexperience. // American Journal of Cardiology. 2003.
- V. 81. - P. 2456-2557.194. Yang H.L., Lin Y.P., Long Y., et al. Predicting cardioembolic stroke with theB-type natriuretic peptide test: a systematic review and meta-analysis.J Stroke Cerebrovas Dis. 2014 Aug;23(7):1882-9.195. Yoshihara F., Nishikimi T., Sasako Y., et al. Plasma atrial natriuretic peptideconcentration inversely correlates with left atrial collagen volume fraction inpatients with atrial fibrillation: plasma ANP as a possible biochemical marker topredict the outcome of the maze procedure. J Am Coll Cardiol.
2002 Jan16;39(2):288-94.196. Youm J.B., Leem C.H., Zhang Y.H., et al. Modeling of arrhythmogenicautomaticity induced by stretch in rat atrial myocytes. Korean J PhysiolPharmacol. 2008 Oct;12(5):267-74.197. Yue L., Feng J., Gaspo R., Li G.R., Wang Z., Nattel S. Ionic remodelingunderlying action potential changes in a canine model of atrial fibrillation. // Circ.Res., 1997, Vol. 815. P. 12–25.198. Zimetbaum P. Amiodarone for atrial fibrillation // N Engl Med.2007; 356:935–941.199. Zimmerman R.S., Edwards E.K, Schawb T.
R. et at. Cardiorenal-endocrinedynamics during and following volume expansion. Am J Physiol 1987: 252: R 336-340119.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
